Dr. David S. Adler

Clinical, Pharmaceutics, MTM

Adler's picture
David S. Adler, Pharm.D.

Professor of Clinical Pharmacy
Associate Dean for Academic Affairs
Skaggs School of Pharmacy and Pharmaceutical Sciences Health Sciences Clinical Professor, Non-Salaried Department of Family and Preventative Medicine

(858) 822-4979
Research Summary

Clinical, Pharmaceutics, MTM

Academic Achievements


B.A. in Biochemistry (1966) UC Berkeley; Pharm.D. (1970) UCSF; ASHP Residency in Pharmacy Practice (1971) UCSF. 

Awards and Honors:

Fellow, California Society of Health-System Pharmacists (1993); Pharmacist of the Year, California Society of Health-System Pharmacists (1987); Outstanding Contribution Award, Boehringer-Mannheim Corp., Science Partner (1995, 1997); Distinguished Service Award, California Society of Health-System Pharmacists (1993); Long’s Award for Excellence in Teaching, UCSF School of Pharmacy (2000, 2002); Academy of Clinical Scholars, UCSD Health Sciences, School of Medicine/School of Pharmacy and Pharmaceutical Sciences (2003 - present). 

Leadership Experience:

Vice Chair, Department of Clinical Pharmacy, UCSF School of Pharmacy (1975- 1996); Associate Director, Department of Pharmacy, University of California Medical Center, San Diego, (1979-2002); Coordinator, UCSD/UCSF ASHP Clinical Pharmacy Residency Program (1977-1992); President, Chair Board of Directors, Chair House of Delegates California Society of Health Systems Pharmacists (1982-1984); Chairman, Planning Committee, Western States Conference for Residents and Preceptors (1986-87); Director of Curriculum UCSD SSPPS (2000-2002); Co-Chair Pfizer and Biogen-Idec Clinical Oncology Fellowship Programs (2007- present). 

  • Concepts in Pharmacy Practice (202A).
  • Contemporary Topics in Pharmacology (SPPS 218A/B).
  • Therapeutics (SPPS 212B).
  • Pharmacogenomics (SPPS 219).
  • Advanced Practice Ambulatory Care Anticoagulation Clinic (SPPS 401 A/B).
  • Pharmacy Law and Ethics (SPPS 204).
Key Contributions
  • Removal of phenytoin by hemodialysis, model for efficacy of evaluating dialysis for treatment of toxicity.
  • Solubility of phenytoin in intravenous solutions.
  • Clinical equivalency and bioavailability of sodium warfarin from multiple sources.
Potential Collaborative Programs
  • Thirty-five years of experience in clinical practice and translational research.
  • Developing novel practice models and diverse approaches to medication therapy management, to improve safe and effective drug therapy treatments.